Abstract
Since decades the urokinase plasminogen activator (uPA) system has been associated with the invasion of malignant cells. The receptor of urokinase (uPAR) is one of the key players in this proteolytic cascade, because it focuses uPAs proteolytic activity to the cell surface and in addition functions as a signaling receptor. uPAR is highly expressed in virtually all human cancers, suggesting possible clinical applications as diagnostic marker, predictive tool of survival or clinical response, and as a target for therapy and imaging. This review summarizes the possibilities of uPAR in clinical applications for cancer patients.
Keywords: uPAR, diagnosis, prognosis, imaging, targeting, therapy, exosomes, tumor, rheumatoid arthritis, AIDS, ELISA, nano-particles, biopsies, Image-guided surgery (IGS), renal threshold
Current Pharmaceutical Design
Title: Clinical Applications of the Urokinase Receptor (uPAR) for Cancer Patients
Volume: 17 Issue: 19
Author(s): Martin C. Boonstra, Hein W. Verspaget, Sjam Ganesh, Frank J.G.M. Kubben, Alexander L. Vahrmeijer, Cornelis J.H. van de Velde, Peter J.K. Kuppen, Paul H.A. Quax and Cornelis F.M. Sier
Affiliation:
Keywords: uPAR, diagnosis, prognosis, imaging, targeting, therapy, exosomes, tumor, rheumatoid arthritis, AIDS, ELISA, nano-particles, biopsies, Image-guided surgery (IGS), renal threshold
Abstract: Since decades the urokinase plasminogen activator (uPA) system has been associated with the invasion of malignant cells. The receptor of urokinase (uPAR) is one of the key players in this proteolytic cascade, because it focuses uPAs proteolytic activity to the cell surface and in addition functions as a signaling receptor. uPAR is highly expressed in virtually all human cancers, suggesting possible clinical applications as diagnostic marker, predictive tool of survival or clinical response, and as a target for therapy and imaging. This review summarizes the possibilities of uPAR in clinical applications for cancer patients.
Export Options
About this article
Cite this article as:
C. Boonstra Martin, W. Verspaget Hein, Ganesh Sjam, J.G.M. Kubben Frank, L. Vahrmeijer Alexander, J.H. van de Velde Cornelis, J.K. Kuppen Peter, H.A. Quax Paul and F.M. Sier Cornelis, Clinical Applications of the Urokinase Receptor (uPAR) for Cancer Patients, Current Pharmaceutical Design 2011; 17 (19) . https://dx.doi.org/10.2174/138161211796718233
DOI https://dx.doi.org/10.2174/138161211796718233 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cancer and Treatment Modalities
Current Cancer Therapy Reviews Combined Therapies of Bone Disease with Bisphosphonates
Current Pharmaceutical Design The Heat Shock Connection of Metabolic Stress and Dietary Restriction
Current Pharmaceutical Biotechnology The Production and Role of Gastrin-17 and Gastrin-17-Gly in Gastrointestinal Cancers
Protein & Peptide Letters Molecular Pharmacology and Pharmacogenomics of Artemisinin and its Derivatives in Cancer Cells
Current Drug Targets Cancer and Stem Cells
Current Cancer Therapy Reviews Novel Therapeutic Approaches to Regulate Human Dihydrofolate Reductase Activity and Expression
Current Enzyme Inhibition The α and β Classes Carbonic Anhydrases from Helicobacter pylori as Novel Drug Targets
Current Pharmaceutical Design MicroRNA-dependent Regulation of Telomere Maintenance Mechanisms: A Field as Much Unexplored as Potentially Promising
Current Pharmaceutical Design Using an Ancient Tool for Igniting and Propagating Immune Tolerance: IDO as an Inducer and Amplifier of Regulatory T Cell Functions
Current Medicinal Chemistry Regulation of the PI3K-Akt Network: Current Status and a Promise for the Treatment of Human Diseases
Current Signal Transduction Therapy AAVs Anatomy: Roadmap for Optimizing Vectors for Translational Success
Current Gene Therapy 5'-Nucleotidases, Nucleosides and their Distribution in the Brain: Pathological and Therapeutic Implications
Current Medicinal Chemistry Recent Patents and Advances in Hepatocyte-Like Cells Differentiation by Perinatal Stem Cells
Recent Patents on Regenerative Medicine An Up-date of Olive Oil Phenols in Inflammation and Cancer: Molecular Mechanisms and Clinical Implications
Current Medicinal Chemistry Targeting Tumor Necrosis Factor Alpha for Alzheimer’s Disease
Current Alzheimer Research Drug Delivery Systems and Strategies to Overcome the Barriers of Brain
Current Pharmaceutical Design Natural Compounds and Plant Extracts as Therapeutics Against Chronic Inflammation in Alzheimer's Disease - A Translational Perspective
CNS & Neurological Disorders - Drug Targets Nanomedicine against Alzheimer’s and Parkinson’s Disease
Current Pharmaceutical Design Ultra-deformable Liposomes as Flexible Nanovesicular Carrier to Penetrate Versatile Drugs Transdermally
Nanoscience & Nanotechnology-Asia